Date: Monday, June 13, 2016
Session Time: 4:30pm-6:00pm
Presentation Time: 5:30pm-5:42pm
Location: Room 306
CMV remains the significant cause of morbidity in transplant recipients. Despite universal prophylaxis, late CMV infection occurs in high proportion of kidney transplant recipients. We aimed to evaluate if a specific viral T-cell response may allow for better identification of recipients at high risk of CMV infection after prophylaxis withdrawal.
Material and methods
We conducted prospective study to analyze the CMV-specific T-cell – mediated immunity in 86 kidney graft recipients subjected to antiviral prophylaxis. 18 CMV- D(+)/R(-),1 D(-)/(R(-) and 67 R(+) were examined within 1st and 3d months after transplantation. We used the Quantiferon-CMV (QF-CMV) assay to measure interferon-γ levels following in vitro stimulation with CMV antigens. Blood samples were monitored for CMV DNAemia using commercial QNAT calibrated to the WHO International Standard. Among 67 CMV R(+) the QF-CMV assay yielded reactive results in 51 (76%) (QF-CMV(+) and negative results in 16 (24%) individuals (QF-CMV(-). In CMV R(-) group 7 of 19 (37%) patients were found to be QF-CMV(+). In overall, 21 of 86 (19%) patients developed CMV viremia after prophylaxis withdrawal within next 12 post-transplant months, including 15 (22%) R(+) and 6 (32%) R(-). Among R(+), CMV infection occurred in 7 out of 16 (44%) recipients that were QF-CMV(-) and in 8 out of 51 (16%) of those QF-CMV(+). In a group of R(-), CMV infection evolved in 5 out of 12 (42%) of those QF-CMV (-), and in 1 out of 7 (14%) of recipients QF-CMV(+). Irrespective of initial CMV IgG status, CMV infection developed in 9 out of 58 (16%) of all QF-CMV(+) patients, and in 12 out of 28 (43%) recipients that were QF-CMV(-).
The use of Quantiferon-CMV assay seems to be useful in CMV infection prediction after prophylaxis withdrawal. In the group of patients subjected to antiviral prophylaxis the negative result of QF-CMV better defines the risk of CMV infection occurrence than initial CMV IgG status.
CITATION INFORMATION: Dęborska-Materkowska D, Perkowska-Ptasińska A, Sadowska A, Sitarek D, Gozdowska J, Ciszek M, Serwańska-Świętek M, Jóźwik A, Domagała P, Kwiatkowski A, Durlik M. Association of Cytomegalovirus-Specific T Cell-Mediated Immunity with the Risk of CMV Infection Occurrence in Kidney Transplant Recipients. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:Dęborska-Materkowska D, Perkowska-Ptasińska A, Sadowska A, Sitarek D, Gozdowska J, Ciszek M, Serwańska-Świętek M, Jóźwik A, Domagała P, Kwiatkowski A, Durlik M. Association of Cytomegalovirus-Specific T Cell-Mediated Immunity with the Risk of CMV Infection Occurrence in Kidney Transplant Recipients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/association-of-cytomegalovirus-specific-t-cell-mediated-immunity-with-the-risk-of-cmv-infection-occurrence-in-kidney-transplant-recipients/. Accessed February 27, 2021.
« Back to 2016 American Transplant Congress